High chemo dosage improves survival for AML patients

12/5/2008 | Yahoo!

Research shows a higher dose of the chemotherapy drug daunorubicin increased median survival rates for patients with previously untreated acute myeloid leukemia, when compared with using the standard dosage. Patients in the high-dose group had overall survival of 23.7 months, compared to 15.1 months for patients in the standard-dose group.

View Full Article in:

Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT